Literature DB >> 9597245

Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994.

L Erickson1, P De Wals.   

Abstract

To study complications and sequelae of serogroup B and C meningococcal disease, a retrospective survey examined the outcome of all culture-proven cases reported in the province of Quebec, Canada, from January 1990 through December 1994 (serogroup B, 167 cases; serogroup C, 304 cases). Data were collected from medical files, postal questionnaires, and telephone interviews. Age groups having the most cases were the 10-19-year age group for serogroup C and the < 1-year age group for serogroup B. Fatality rates were 7% for serogroup B and 14% for serogroup C disease. Only 3% of survivors of serogroup B disease had physical sequelae, compared with 15% of survivors of serogroup C disease (skin scars, 12%; amputations, 5%; hearing loss, 2%; renal problems, 1%; and other sequelae, 4%). These results confirm the gravity of disease caused by serogroup C, serotype 2a Neisseria meningitidis and justify liberal use of vaccination for outbreak control.

Entities:  

Mesh:

Year:  1998        PMID: 9597245     DOI: 10.1086/520303

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  49 in total

1.  Meningococcal disease: oh no, not another childhood vaccine.

Authors:  Erica Weir
Journal:  CMAJ       Date:  2002-04-16       Impact factor: 8.262

Review 2.  Recognition, treatment and complications of meningococcal disease.

Authors:  F A Riordan; A P Thomson
Journal:  Paediatr Drugs       Date:  1999 Oct-Dec       Impact factor: 3.022

Review 3.  Reprogramming the host response in bacterial meningitis: how best to improve outcome?

Authors:  M van der Flier; S P M Geelen; J L L Kimpen; I M Hoepelman; E I Tuomanen
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

4.  Use of corticosteroids and other adjunct therapies for acute bacterial meningitis in adults.

Authors:  Kameshwar Prasad; Nirendra Kumar Rai; Amit Kumar
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

Review 5.  The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine.

Authors:  Robert Welte; Caroline L Trotter; W John Edmunds; Maarten J Postma; Philippe Beutels
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

6.  Challenges to the surveillance of meningococcal disease in an era of declining incidence in montréal, Québec.

Authors:  Ruwan Ratnayake; Robert Allard
Journal:  Can J Public Health       Date:  2013-05-14

7.  Counting the cost of meningococcal disease : scenarios of severe meningitis and septicemia.

Authors:  Claire Wright; Rebecca Wordsworth; Linda Glennie
Journal:  Paediatr Drugs       Date:  2013-02       Impact factor: 3.022

Review 8.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

9.  Phenotypic and genetic characterization of a unique variant of serogroup C ET-15 meningococci (with the antigenic formula C:2a:P1.7,1) causing invasive meningococcal disease in Quebec, Canada.

Authors:  Raymond S W Tsang; Chao Ming Tsai; Peixuan Zhu; Louise Ringuette; Manon Lorange; Dennis K S Law
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

10.  Should university students be vaccinated against meningococcal disease in Canada?

Authors:  Philippe De Wals
Journal:  Can J Infect Dis       Date:  2004-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.